Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | IDE | P14735 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | HLCS | P50747 | 6/20 | 0.54 |
| ▸ | CA12 | O43570 | 6/20 | 0.48 |
| ▸ | CA1 | P00915 | 6/20 | 0.48 |
| ▸ | CA2 | P00918 | 6/20 | 0.48 |
| ▸ | CA9 | Q16790 | 6/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15647842 | 0.92 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL15053200 | 0.91 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL23066879 | 0.91 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL5091193 | 0.91 | TDP1 (0.89) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL629531 | 0.90 | TDP1 (0.74) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL2536441 | 0.89 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| Hydrochloric Acid SCHEMBL3417755 | 0.88 | TDP1 (0.61) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL8011736 | 0.88 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL8011738 | 0.88 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL693036 | 0.87 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118829725-A | Method for producing cells | 莱尔免疫制药公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-115537372-A | Antigen presenting cell mimetic scaffolds and methods of making and using same | 哈佛学院院长等 | 2022-12-30 | — | — | CN | disclosed |
| CN-115404196-A | Antigen presenting cell mimetic scaffolds and methods of making and using same | 哈佛学院院长等 | 2022-11-29 | — | — | CN | disclosed |
| CN-115305229-A | Antigen presenting cell mimetic scaffolds and methods of making and using same | 哈佛学院院长等 | 2022-11-08 | — | — | CN | disclosed |
| EP-3110841-B1 | PEPTIDES AND METHODS OF USE | BAXALTA INC (US) | 2021-03-31 | — | — | EP | disclosed |
| US-10124033-B2 | Peptides and methods of use | BAXALTA INCORPORATED (US) | 2018-11-13 | — | — | US | disclosed |
| US-10093712-B2 | Immunostimulatory compositions and uses thereof | SUSAVION BIOSCIENCES, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180263692-A1 | DEVICES FOR DAMAGING NERVES AND RELATED METHODS OF USE | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2018-09-20 | — | — | US | disclosed |
| US-20170035835-A1 | PEPTIDES AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| EP-3110841-A1 | PEPTIDES AND METHODS OF USE | Baxalta Incorporated (US) | 2017-01-04 | — | — | EP | disclosed |
| WO-2005037190-A2 | MULTIPLEX VACCINES | DENDRITHERAPEUTICS, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050079131-A1 | Emulsion particles for imaging and therapy and methods of use thereof | KEREOS, INC. | 2005-04-14 | — | — | US | disclosed |
| WO-2005014051-A1 | EMULSION PARTICLES FOR IMAGING AND THERAPY AND METHODS OF USE THEREOF | BARNES-JEWISH HOSPITAL (US) | 2005-02-17 | — | — | WO | disclosed |
| WO-2002060524-A9 | ENHANCED ULTRASOUND DETECTION WITH TEMPERATURE DEPENDENT CONTRAST AGENTS | BARNES JEWISH HOSPITAL (US) | 2004-01-08 | — | — | WO | disclosed |
| EP-1363538-A2 | ENHANCED ULTRASOUND DETECTION WITH TEMPERATURE DEPENDENT CONTRAST AGENTS | Barnes-Jewish Hospital (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002060524-A2 | ENHANCED ULTRASOUND DETECTION WITH TEMPERATURE DEPENDENT CONTRAST AGENTS | BARNES-JEWISH HOSPITAL (US) | 2002-08-08 | — | — | WO | disclosed |
| US-20020102216-A1 | Enhanced ultrasound detection with temperature-dependent contrast agents | KEREOS, INC. | 2002-08-01 | — | — | US | disclosed |
| US-6133038-A | Platinum-containing compounds methods for their preparation and applications thereof | KREATECH DIAGNOSTICS (NL) | 2000-10-17 | — | — | US | disclosed |
| US-5985566-A | Platinum-containing compounds, methods for their preparation and applications thereof | KREATECH DIAGNOSTICS (NL) | 1999-11-16 | — | — | US | disclosed |
| US-5714327-A | PLATINUM CONTAINING DETECTABLE PROBE COMPOUND HAVING MARKER MOIETY, STABILIZING SUBSTITUENTS, BIOMOLECULE | KREATECH DIAGNOSTICS (NL) | 1998-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050079131-A1 | Emulsion particles for imaging and therapy and methods of use thereof | LIPA, PHOSPHO1, PLIN3 | TDP1 4341/4885MEN1 2210/4885ABL1 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.